²³¹Fªº¥Í©R¬ì¾Ç¨Æ°È³¡´£¨Ñ»P²³¤£¦Pªºªk«ß©M§Þ³N©Ê§Þ¯àªºµ²¦X¡A?«È¤á¦b¨îÃÄ¡B¥Íª«§Þ³N¤ÎÂåÀø³]³Æ?·~»â°ì´£¨Ñ°ª«×±M·~¤ÆªºªA°È¡C
§Ú̪º¥Í©R¬ì¾Ç·~°È«È¤á¥]¬A¸ó°ê¨îÃÄ¥ø·~¡B§¹¥þ¤@Å餯ªº¥Íª«¨îÃÄ¥ø·~¡B¶EÂ_©MÂåÀø¾¹±ñ¥ø·~¡B®ø¶O?«~¥ø·~¡BÀç¾i¹«~¥ø·~¡B¬ã¨s¾÷ºc¡B¤j¾Ç¡B¨p¤HªÑ¥»°òª÷¥H¤Î¬¡ÅD¦b¥Í©R¬ì¾Ç»â°ìªº§ë¸ê»È¦æ¾÷ºc¡C
¸Ó¨Æ°È³¡ªº³\¦h«ß®v³£¨ã¦³¬ÛÃö¾Ç¬ìªº³Õ¤h©ÎºÓ¤h¾Ç¦ì¡A³o¨Ç¾Ç¬ì¥]¬A¤À¤l¥Íª«¾Ç¡BÂo¹L©Ê·L¥Íª«¾Ç¡B§K¬Ì¾Ç¡B¿ò¶Ç¾Ç¡B¯«¸g¥Íª«¾Ç¡Bµ²ºc¥Íª«¾Ç¡B½ÆÂø¥Íª«¤ÀªR¾Ç¡Bª«²z¾Ç¡B¦³¾÷¤Æ¾Ç¡BÂåÃĤƾǥH¤Î¥Íª«Âå¾Ç¤uµ{¡C
§ÚÌ?¥Í©R¬ì¾Ç«È¤á¦b¬ÛÃö§Þ³N¤è±´£¨Ñ¥þ¤è¦ìªºªk«ßªA°È¡A¥]¬A¡G
-
±M§Q»P°Ó¼Ð²Õ¦X¾Ô²¤¡B³Ð§@»PºÞ²z¡C
-
ª¾ÃÑ?Åv¶D³^¡A¥]¬A±M§Q«IÅv»Pª§Ä³¡C
-
ª¾ÃÑ?Åv¤è±ªºÆ[ÂI¡A¥]¬A¦³®Ä©Ê¡B«IÅv¡B¥H¤Î¦P¦æµû»ù¡C
-
¿Ä¸ê¡B¦X¨Ö»P¦¬Áʪº¼f·V¼f®Ö¡C
-
§Þ³N¬ÛÃö¨óij¡A¥]¬A¹ï¸ó°ê³\¥i¡B¨ó§@¡B¦X¹Ù¬ãµo¥H¤Î¿Ô¸ßªº²`¤JÁA¸Ñ¡C
-
¤ÏÃbÂ_©M¤½¥Ävª§ªk¡C
-
µ|°È¡C
²³¹F¦b»P¡m«¢©_-ºû§J´µ°Òªk®×¡n¡]Hatch-Waxman Act¡^¬ÛÃöªºÅU°Ý»P¶D³^¤è±²`¦³³y¸Ú¡A¥]¬A»P±M§Q¾Ô²¤¤Î¹ê¬IÁpôºò±Kªºªk³W©Ê°ÝÃD©M¤ÏÃbÂ_°ÝÃD¡C
§Ú̪º§V¤O¨ó§U«È¤áÀò±o¤F¥¨¤jªº¦¨¥\¡A¥]¬A¤Uz®×¨Ò¡G
-
¥Nªí²ÓM°ò¦]¤½¥q¡]Celgene¡^ªº±M§Q¾Ô²¤¡B³\¥i¥H¤Î»P¨äTHALOMID? ©MÃþ¦üª«¬ÛÃöªº±M§Q°õ¦æ·~°È¡C
-
¥NªíÂå¾Ç§K¬Ì¤½¥q¡]MedImmune¡^¥H¤ÎÂå¾Ç§K¬Ì¬Ì]¤½¥q¡]MedImmune Vaccines¡^¡A¶i¦æ»P¨äEthyol?¡BSynagis?¡BNumax?¥H¤Î°ò¦]Åܺجy¦æ©Ê·P«_¬Ì]¬ÛÃöªº±M§Q²Õ¦Xªº¥Ó½Ð»P¹ê¬I¡C
-
¥NªíÀN¤Ò°Òù¤ó¤½¥q¡]Hoffmann-La Roche¡^³B²z¯A¤Î¤zÂZ¯Àªº¦h°_½Ä¬ð¡C
-
¥Nªí°ò¦]¤uµ{§Þ³N¤½¥q¡]Genentech, Inc.¡^¶i¦æ»P¦å¤Í¯f²ÄVIII¦]¼Æ¬ÛÃöªº±M§Q«IÅv¶D³^¡C
-
¥Nªí¯SùجüùØ´µ¨îÃĤ½¥q¡]Trimeris Pharmaceuticals, Inc.¡^±q¨Æ»P¨ä§Ü¦ã´þ¯fÃĪ«FUZEON?¬ÛÃöªº±M§Q²Õ¦Xªº¥Ó½Ð»PÅGÅ@¡C
Ápµ¸
Laura A. Coruzzi Ph.D.
New York
¹q¸Ü: 1.212.326.3939
¹q¤l¶l¥ó
Anthony M. Insogna
San Diego
¹q¸Ü: 1.858.314.1200
¹q¤l¶l¥ó
Peter Homberg
Munich
¹q¸Ü: 49.89.20.60.42.200
¹q¤l¶l¥ó